European Heart Journal Advance Access published online on September 5, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn387
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
1 Department of Vascular Medicine, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
2 Department of Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands
Received 1 April 2008; revised 7 July 2008; accepted 14 August 2008.
* Corresponding author. Tel: +31 30 2509111, Fax: +31 30 2505488, Email: f.l.j.visseren{at}umcutrecht.nl
The classical perception of adipose tissue as a storage place of fatty acids has been replaced over the last years by the notion that adipose tissue has a central role in lipid and glucose metabolism and produces a large number of hormones and cytokines, e.g. tumour necrosis factor-
, interleukin-6, adiponectin, leptin, and plasminogen activator inhibitor-1.
The increased prevalence of excessive visceral obesity and obesity-related cardiovascular risk factors is closely associated with the rising incidence of cardiovascular diseases and type 2 diabetes mellitus. This clustering of vascular risk factors in (visceral) obesity is often referred to as metabolic syndrome. The close relationship between an increased quantity of visceral fat, metabolic disturbances, including low-grade inflammation, and cardiovascular diseases and the unique anatomical relation to the hepatic portal circulation has led to an intense endeavour to unravel the specific endocrine functions of this visceral fat depot. The objective of this paper is to describe adipose tissue dysfunction, delineate the relation between adipose tissue dysfunction and obesity and to describe how adipose tissue dysfunction is involved in the development of diabetes mellitus type 2 and atherosclerotic vascular diseases. First, normal physiology of adipocytes and adipose tissue will be described.
Key Words: Adipocyte dysfunction • Adipose tissue • Metabolic syndrome • Insulin resistance • Adiponectin • Type 2 diabetes mellitus • Atherosclerosis • Cardiovascular disease • Leptin • TNF- • Interleukin-6 • Review
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Martin, S. Okano, C. Kistler, M. A. Fernandez-Rojo, M. M. Hill, and R. G. Parton Spatiotemporal Regulation of Early Lipolytic Signaling in Adipocytes J. Biol. Chem., November 13, 2009; 284(46): 32097 - 32107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C.M. van Kruijsdijk, E. van der Wall, and F. L.J. Visseren Obesity and Cancer: The Role of Dysfunctional Adipose Tissue Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Young, C. D. Engelman, C. D. Langefeld, K. G. Hairston, S. M. Haffner, M. Bryer-Ash, and J. M. Norris Association of Plasma Vitamin D Levels with Adiposity in Hispanic and African Americans J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3306 - 3313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Meydani and A. Azzi Diabetes risk: antioxidants or lifestyle? Am. J. Clinical Nutrition, August 1, 2009; 90(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, H. J. Shin, E. L. Ding, and R. M. van Dam Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis JAMA, July 8, 2009; 302(2): 179 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yu, X. Ye, J. Wang, Q. Qi, O. H. Franco, K. L. Rennie, A. Pan, H. Li, Y. Liu, F. B. Hu, et al. Associations of Physical Activity With Inflammatory Factors, Adipocytokines, and Metabolic Syndrome in Middle-Aged and Older Chinese People Circulation, June 16, 2009; 119(23): 2969 - 2977. [Abstract] [Full Text] [PDF]
|
|